Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
Healthcare
$4.07 +1.13%
+$0.05 today
- Market cap
- $623.90M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
52W Low $3.04High $5.10
Volume 2.44M
Average 1.76M
Balance Sheet
Inspect the capital base behind the business.
Assets
$94.62M
FY 2025 · Annual
-28.2% YoYLiabilities
$18.04M
FY 2025 · Annual
-47.5% YoYEquity
$76.58M
FY 2025 · Annual
-21.4% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 109.28M | 30.78M | 26.29M | 36.33M | 18.01M |
| Short-term Investments | 46.04M | 116.14M | 99.72M | 86.29M | 73.46M |
| Net Receivables | 899K | 1.35M | 1.78M | 2.41M | 1.75M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.87M | 4.25M | 2.28M | 1.24M |
| Total Current Assets | 160.66M | 151.14M | 132.03M | 127.32M | 94.46M |
| Property, Plant & Equipment (Net) | 8.07M | 6.81M | 6.09M | 4.36M | 32K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 35.69M | 37.36M | 6.28M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 61K | 103K | 0 | 34K | 130K |
| Total Non-current Assets | 43.82M | 44.28M | 12.37M | 4.39M | 162K |
| Total Assets | 204.49M | 195.42M | 144.4M | 131.71M | 94.62M |
| Account Payables | 3.17M | 3.52M | 3.22M | 2.32M | 1.17M |
| Short-term Debt | 383K | 372K | 0 | 0 | 547K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 16.46M | 11.79M | 7.57M | 0 |
| Other Current Liabilities | 3.39M | 8.78M | 3.7M | 0 | 2.13M |
| Total Current Liabilities | 11.22M | 32.86M | 22.49M | 15.62M | 6.01M |
| Long-term Debt | 16.3M | 10.37M | 6.95M | 4.83M | 3.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 6M | 0 | 2.86M | 0 |
| Other Non-current Liabilities | 5.3M | 7.53M | 7.6M | 10.23M | 8.4M |
| Total Non-current Liabilities | 23.83M | 25.71M | 15.9M | 18.72M | 12.04M |
| Total Liabilities | 35.05M | 58.57M | 38.38M | 34.34M | 18.04M |
| Common Stock | 1.29B | 1.32B | 1.35B | 1.41B | 1.42B |
| Retained Earnings | (1.13B) | (1.2B) | (1.28B) | (1.35B) | (1.38B) |
| Accumulated OCI | (48.33M) | (50.49M) | (48.42M) | (48.14M) | (48.1M) |
| Other Stockholders Equity | (1) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 169.44M | 136.85M | 106.02M | 97.37M | 76.58M |
| Total Debt | 18.91M | 12.55M | 8.72M | 6.12M | 4.19M |
| Net Debt | (90.37M) | (18.22M) | (17.56M) | (30.21M) | (13.82M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $23.7M |
| Short-term Investments | $71.5M |
| Receivables | $1.3M |
| Other Current | $180.5M |
| Total Current Assets | $277.0M |
| PP&E (Net) | $22.0K |
| Other Non-current | $131.0K |
| Total Non-current Assets | $153.0K |
| Total Assets | $277.2M |
Analysis
Selected assets total $277.2M for Latest. The largest visible component is Other Current at $180.5M, about 65.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 22, 2026 |
How much cash does ABUS have?
Arbutus Biopharma Corporation (ABUS) reported $18.01M in cash and equivalents in fiscal 2025.
How much debt does ABUS carry?
Arbutus Biopharma Corporation (ABUS) reported $4.19M of total debt, with net debt of -$13.82M.
Continue the stock analysis
Jump to another research area for this company.